Mission

Our mission is to improve patient outcomes and expand healthcare access by democratizing echocardiograms – the most commonly used tool for the detection of heart risk – through the use of AI.

Us2 is building a future where everyone, from the most advanced tech-driven regions to the most resource-constrained communities, can have equal access to high quality, consistent and inexpensive echo analysis.

Cardiovascular disease is the #1 killer worldwide and is the cause of 1 in 3 deaths – but it doesn’t have to be that way

Our story

31
31
Group 188

2017 – Us2.ai (formerly Eko.ai) is the first spinout of an 11-country cardiovascular research platform supported by Singapore’s Agency for Science, Technology and Research (A*Star).

With data science support from Singapore’s top 3 research institutes, the company quickly developed an initial release, won multiple tech startup awards, and signed commercial agreements with key pharma partners.

2019 – Us2.ai closes a USD 4.5 million seed round led by Sequoia Capital and EDBI.

2021 – First regulatory clearance with the FDA, soon followed by clearances in Canada, Australia and New Zealand.

2022 – The company closes a USD 15 million Series A led by IHH Healthcare and Heal Partners, joined by returning and new investors Sequoia Capital, EDBI, Partech, Pappas Capital and others.

Group 190
Us2 Ai History
Us2 Ai History
Quote

Us2.ai surpasses current echo solutions that focus on semi-automation or black box AI or just single measurements. We deliver a complete solution: zero clicks, full report.

- James Hare, CEO & Co-founder

Our team

Team Members

Sorry, we couldn't find any posts. Please try a different search.

Advisors
Martincowie
Dr. Martin Cowie

Martincowie
Dr. Martin Cowie

Dr. Martin Cowie currently serves as the Chair of the European Society of Cardiology Digital Health Committee, the Chair of Cardiology at the Imperial College London and the Honorary Consultant Cardiologist at the Royal Brompton Hospital. As the ex-Chair of the British Society for Heart Failure and a current member of the European Society of Cardiology’s EU Affairs Committee, Martin’s research interests lie in health technology assessments, with a particular focus on new technologies such as diagnostics, drugs and devices. He holds an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine.

Bijandorri
Dr. Bijan Dorri

Bijandorri
Dr. Bijan Dorri

The MedTech Advisor for A*STAR (Agency for Science, Technology, and Research) in Singapore since 2014, Dr. Bijan Dorri is an Affiliate Professor in Mechanical Engineering and Radiology at the University of Washington. Dr. Dorri sits on multiple boards, including University of Washington’s Bio-Engineering and Mechanical Engineering External Advisory Boards, Engineering In Health Advisory Board, ASTAR’s Health-Tech and Precision Medicine Cluster Advisory Board and the ST Engineering’s Med-Tech Science and Business Advisory Board.

Prior, Dr. Dorri spent 30 years at General Electric Company in various technology and operational leadership roles and was the CTO of GE Healthcare Systems, a $13B medical devices business. He holds a BS Degree in Chemical Engineering from Shiraz University in Iran, an MS Degree in Industrial Engineering, and PhD in Mechanical Engineering from the University of Washington.

Kenstein
Dr. Ken Stein

Kenstein
Dr. Ken Stein

Dr. Ken Stein is currently Senior Vice President and Chief Medical Officer for Rhythm Management and Global Health Policy at Boston Scientific. He is a Phi Beta Kappa graduate of Harvard College and earned his MD from New York University School of Medicine after completing his medical internship, residency, cardiology and cardiac electrophysiology training at The New York-Presbyterian Hospital/Weill Cornell Medical Center.

Jeremylim
Dr. Jeremy Lim

Jeremylim
Dr. Jeremy Lim

Mr Jeremy Lim is Partner, Health & Life Sciences Asia Pacific, at Oliver Wyman and advises senior officials at public sector agencies, multinationals, private and NGO clients on national and regional go-to-market plans and implementation strategies, government engagement and public-private partnerships. Dr. Lim is also a lecturer at the National University of Singapore (Saw Swee Hock School of Public Health and Duke-NUS Medical School) and is the author of ‘Myth or Magic: The Singapore Healthcare System’, which draws lessons from the Singapore health system for health reform efforts in other countries.

Scottsolomon
Dr. Scott Solomon

Scottsolomon
Dr. Scott Solomon

Dr. Scott D. Solomon, MD is the Edward D. Frohlich Distinguished Chair, Professor of Medicine at Harvard Medical School and Senior Physician at Brigham and Women’s Hospital. He received his A.B. from Williams College and his MD from Harvard Medical School. 

Justin
Dr. Justin Ezekowitz

Justin
Dr. Justin Ezekowitz

A professor of medicine in the Division of Cardiology, Dr. Justin A. Ezekowitz completed his MSc in clinical epidemiology as well as his cardiology fellowship at the University of Alberta. He is also the co-director of the Canadian VIGOUR Centre at the University of Alberta and has overseen the operations of five new heart failure clinics across Alberta in view of providing better access to speciality services. He co-chairs the initiative on a heart failure care pathway as part of the Alberta Health Services Strategic Clinical Networks. Finally, Dr. Ezekowitz is a cardiologist at the Mazankowski Alberta Heart Institute, focused principally on heart failure, and at the same time works at the Heart Function Clinic.